PARP1 and breast cancer: Here, we summarize the clinical studies of PARP inhibitors, including olaparib, talazoparib, veliparib, niraparib, and rucaparib, in BRCA1/2-associated BC patients, in Table 3, and briefly mention several representative phase III trials among them.